Nicotinamide adenine dinucleotide — abbreviated NAD+ — is one of the most-studied coenzymes in longevity science. It participates in over 500 enzymatic reactions, sits at the heart of mitochondrial ATP production, and feeds the sirtuin and PARP pathways that govern DNA repair, circadian rhythm, and metabolic flexibility. By middle age, tissue NAD+ pools in humans have typically fallen to roughly half of youthful levels, and the decline tracks with reduced oxidative capacity, slower recovery, and the dyslipidaemia / insulin-resistance cluster that defines cardiometabolic ageing.
For South African readers the conversation is especially relevant: high-carbohydrate staple diets, sleep debt driven by load-shedding, and rising rates of metabolic syndrome all converge on pathways that NAD+ depletion accelerates. This post walks through what 2026 evidence actually says about restoring NAD+ — not the marketing claims, but the published trials.
Why NAD+ matters — the three systems it powers
Mitochondrial respiration. NAD+ accepts electrons in Complex I of the electron transport chain. Without enough of it, the chain stalls, ATP yield drops, and reactive oxygen species rise. This is the substrate-level reason people report "energy" when NAD+ is restored.
Sirtuin signalling. SIRT1, SIRT3, and SIRT6 are NAD+-dependent deacetylases that regulate insulin sensitivity, mitochondrial biogenesis, inflammation, and circadian gene expression. They behave like metabolic switches, and their activity scales with available NAD+.
DNA repair. PARP enzymes consume NAD+ to flag and repair single- and double-strand breaks. Chronic PARP activation — driven by obesity, alcohol, or pollutant exposure — can drain NAD+ pools and starve the sirtuins of substrate. A 2024 Nature Aging review framed NAD+ restoration as "supply-side repair" of this drain.
The precursor landscape: NMN, NR, and beyond
Direct NAD+ supplementation is limited by poor oral bioavailability — the molecule does not cross cell membranes efficiently. The clinical pipeline has therefore concentrated on precursors the body can convert to NAD+ internally:
NMN (nicotinamide mononucleotide). One enzymatic step from NAD+. A 2022 Washington University placebo-controlled trial in postmenopausal women with prediabetes showed improved insulin sensitivity in skeletal muscle after 10 weeks of 250 mg/day NMN, with a follow-up 2023 Science report demonstrating enhanced aerobic capacity in amateur runners. A 2025 Cell Reports Medicine extension study in 50–80 year-olds replicated the insulin-sensitivity finding and added a modest improvement in walking speed.
NR (nicotinamide riboside). Two steps from NAD+. The Niagen brand NR has been studied in over 25 published human trials. A 2023 European Journal of Nutrition meta-analysis pooled eight RCTs and found a consistent ~25–30% rise in whole-blood NAD+ across doses from 100 mg to 1,000 mg daily, though clinical-outcome endpoints (insulin sensitivity, blood pressure) were more variable than the biomarker shift would predict.
Trigonelline, nicotinamide, and emerging precursors. Coffee-derived trigonelline is being studied as a lower-cost NAD+-boosting route. Plain nicotinamide (vitamin B3 form) also raises NAD+ but inhibits sirtuins at high doses, which limits its longevity utility. A 2026 review in Annual Review of Nutrition argued that "the precursor question is largely solved; the open question is delivery and tissue specificity."
What 2026 evidence does — and does not — support
Strong support: blood NAD+ rises reliably with NMN and NR supplementation at studied doses; this has been reproduced in over thirty human trials. Biomarker improvement (insulin sensitivity, vascular function in 60+ populations) is consistent in mid-life and older adults with metabolic dysfunction.
Moderate support: performance benefits in already-healthy populations are smaller. A 2025 RCT in competitive cyclists found NR improved time-to-exhaustion by ~5% in 40+ athletes but had no measurable effect in under-30s. The likely ceiling is set by baseline NAD+ status — if you are not depleted, you cannot meaningfully replete further.
Unproven / under-studied: hard clinical-outcome endpoints — cardiovascular events, dementia incidence, lifespan extension — remain unstudied at the scale required. The longevity claims circulating on social media extrapolate from C. elegans and mouse data to humans in ways the evidence does not yet support.
How this fits into a BioMuti stack
BioMuti's NAD+ 1000mcg is positioned as part of a multi-pathway metabolic stack alongside Retatrutide and MOTS-c, both of which also act on mitochondrial energetics. For South African users thinking practically about cellular longevity, the evidence points to three levers that work together rather than one supplement that does everything:
Sleep regularity. A 2024 Cell paper showed that sleep fragmentation in 50+ adults reduced morning NAD+ levels by ~15% relative to age-matched controls with stable sleep. Restoring a consistent 7–8 hour window matters as much as any precursor.
Resistance training. A 2023 RCT found that 12 weeks of resistance exercise raised skeletal-muscle NAD+ by ~20% in sedentary 55–70 year-olds — comparable to low-dose NR in the same study. The combination outperformed either alone.
Diet pattern. Diets rich in tryptophan, vitamin B3, and bioavailable protein support de novo NAD+ synthesis. The Mediterranean-style pattern most often studied in this context is easily adapted to a South African plate by emphasising fish, legumes, and olive oil.
Safety and regulatory notes
NMN's regulatory status has shifted. After the FDA declined to classify NMN as a dietary supplement in 2022 (it was investigated as a drug), the supplement route narrowed but did not close. South African consumers should look for third-party tested products with a CoA available. NR is generally recognised as safe (GRAS) in the US. At studied doses both precursors are well tolerated; flushing (a niacin-like effect) is uncommon at under 1 g/day.
This post is informational, not a clinical recommendation. Speak to a healthcare provider before starting any precursor, especially if you are on lipid-lowering medication, are pregnant, or have a cancer history — PARP- and sirtuin-modulating compounds interact with several common drug classes.
The bottom line
NAD+ precursors are among the better-evidenced longevity interventions available in 2026. They reliably raise a key biomarker, modestly improve metabolic function in depleted populations, and have a clean short-term safety profile. They are not a substitute for sleep, training, or diet — but layered onto those foundations, the data is finally strong enough to recommend with caveats. For BioMuti customers exploring metabolic and longevity support, the broader stack combines NAD+ restoration with the peptides and botanicals most often studied alongside it.
References and further reading: